202 related articles for article (PubMed ID: 17582599)
21. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
22. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
23. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Kadouri L; Sagi M; Goldberg Y; Lerer I; Hamburger T; Peretz T
Breast Cancer Res Treat; 2013 Jul; 140(1):207-11. PubMed ID: 23824362
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage.
Nieuwenhuis B; Van Assen-Bolt AJ; Van Waarde-Verhagen MA; Sijmons RH; Van der Hout AH; Bauch T; Streffer C; Kampinga HH
Int J Radiat Biol; 2002 Apr; 78(4):285-95. PubMed ID: 12020440
[TBL] [Abstract][Full Text] [Related]
27. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
28. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
29. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
[TBL] [Abstract][Full Text] [Related]
30. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
31. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
32. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
33. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Rothfuss A; Schütz P; Bochum S; Volm T; Eberhardt E; Kreienberg R; Vogel W; Speit G
Cancer Res; 2000 Jan; 60(2):390-4. PubMed ID: 10667592
[TBL] [Abstract][Full Text] [Related]
34. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
[TBL] [Abstract][Full Text] [Related]
35. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
37. Elevated radiation-induced γH2AX foci in G2 phase heterozygous BRCA2 fibroblasts.
Beucher A; Deckbar D; Schumann E; Krempler A; Frankenberg-Schwager M; Löbrich M
Radiother Oncol; 2011 Oct; 101(1):46-50. PubMed ID: 21665305
[TBL] [Abstract][Full Text] [Related]
38. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
Narod SA; Lubinski J; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Rosen B; Kim-Sing C; Isaacs C; Domchek S; Sun P;
Lancet Oncol; 2006 May; 7(5):402-6. PubMed ID: 16648044
[TBL] [Abstract][Full Text] [Related]
39. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Antoniou AC; Beesley J; McGuffog L; Sinilnikova OM; Healey S; Neuhausen SL; Ding YC; Rebbeck TR; Weitzel JN; Lynch HT; Isaacs C; Ganz PA; Tomlinson G; Olopade OI; Couch FJ; Wang X; Lindor NM; Pankratz VS; Radice P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Viel A; Allavena A; Dall'Olio V; Peterlongo P; Szabo CI; Zikan M; Claes K; Poppe B; Foretova L; Mai PL; Greene MH; Rennert G; Lejbkowicz F; Glendon G; Ozcelik H; Andrulis IL; ; Thomassen M; Gerdes AM; Sunde L; Cruger D; Birk Jensen U; Caligo M; Friedman E; Kaufman B; Laitman Y; Milgrom R; Dubrovsky M; Cohen S; Borg A; Jernström H; Lindblom A; Rantala J; Stenmark-Askmalm M; Melin B; ; Nathanson K; Domchek S; Jakubowska A; Lubinski J; Huzarski T; Osorio A; Lasa A; Durán M; Tejada MI; Godino J; Benitez J; Hamann U; Kriege M; Hoogerbrugge N; van der Luijt RB; van Asperen CJ; Devilee P; Meijers-Heijboer EJ; Blok MJ; Aalfs CM; Hogervorst F; Rookus M; ; Cook M; Oliver C; Frost D; Conroy D; Evans DG; Lalloo F; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Hodgson S; Morrison PJ; Porteous ME; Walker L; Kennedy MJ; Dorkins H; Peock S; ; Godwin AK; Stoppa-Lyonnet D; de Pauw A; Mazoyer S; Bonadona V; Lasset C; Dreyfus H; Leroux D; Hardouin A; Berthet P; Faivre L; ; Loustalot C; Noguchi T; Sobol H; Rouleau E; Nogues C; Frénay M; Vénat-Bouvet L; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Dressler AC; Gschwantler-Kaulich D; Pfeiler G; Hansen TV; Jønson L; Agnarsson BA; Kirchhoff T; Offit K; Devlin V; Dutra-Clarke A; Piedmonte M; Rodriguez GC; Wakeley K; Boggess JF; Basil J; Schwartz PE; Blank SV; Toland AE; Montagna M; Casella C; Imyanitov E; Tihomirova L; Blanco I; Lazaro C; Ramus SJ; Sucheston L; Karlan BY; Gross J; Schmutzler R; Wappenschmidt B; Engel C; Meindl A; Lochmann M; Arnold N; Heidemann S; Varon-Mateeva R; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Kast K; Schönbuchner I; Caldes T; de la Hoya M; Aittomäki K; Nevanlinna H; Simard J; Spurdle AB; Holland H; Chen X; ; Platte R; Chenevix-Trench G; Easton DF;
Cancer Res; 2010 Dec; 70(23):9742-54. PubMed ID: 21118973
[TBL] [Abstract][Full Text] [Related]
40. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
